Mapping the prediction-invisible fraction of an engineered immunopeptidome: a pilot analysis of immunoproteasome-reprogrammed mesenchymal stromal cells
Abstract
Algorithms that predict which peptides the immune system sees are central to cancer vaccine design, yet they are trained almost entirely on binding affinity and remain largely blind to how the antigen-processing machinery shapes the repertoire that reaches the cell surface. Mesenchymal stromal cells engineered to express the immunoproteasome (MSC-IPr) are a whole-cell vaccine platform that presents a larger and chemically distinct peptide repertoire than dendritic cells. Here we use a pilot immunopeptidomics dataset from that platform to ask how much of a processing-reprogrammed repertoire current prediction models can see. Of 234 peptides detected only after tumour-lysate pulsing, 34 (14.5%) were empirically eluted from MHC class I yet scored as non-binders by NetMHCpan-4.1, MHCflurry affinity and MHCflurry presentation simultaneously. This is twenty-fold the rate obtained by applying identical criteria to an independently generated C57BL/6 immunopeptidome atlas (0.65%). These peptides are weak binders rather than true non-binders, and an orthogonal immunogenicity model ranks them modestly above the predictable majority. They are associated with a candidate non-canonical anchor pattern: an aspartate at P2 that is positional rather than compositional (3.4-fold above a composition-preserving null) and absent from catalogued H2-Db epitope space. Because the dataset comprises single mass-spectrometry runs without a proteasome-matched control, we present these as pilot observations, not established effects. We propose the engineered-processing strategy they illustrate, in which cells with defined, non-canonical processing serve as an empirical filter for epitope discovery, and we specify the replication, spectral-validation and control arms required to test it.
Related
- TGFB1-Engineered Induced Mesenchymal Stromal Cells Exhibit High Immunomodulatory Potency and Durably Reprogram Synovial Macrophages in Osteoarthritis
- HLA-Engineered iPSC-Derived Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Mice
- DNA methylation-based prediction of differentiation state at cell-type resolution reveals an age-associated epigenetic mesenchymal drift
- 902 Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy
- Inhibition of cellular NEDDylation partially alters the MHC class I immunopeptidome
BibTeX
@article{shammaa2026mapping,
title = {{Mapping the prediction-invisible fraction of an engineered immunopeptidome: a pilot analysis of immunoproteasome-reprogrammed mesenchymal stromal cells}},
author = {Riam Shammaa and Jamilah Abusarah and Moutih Rafei and Nehme El-Hachem},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1997527},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1997527},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Mapping the prediction-invisible fraction of an engineered immunopeptidome: a pilot analysis of immunoproteasome-reprogrammed mesenchymal stromal cells
AU - Riam Shammaa
AU - Jamilah Abusarah
AU - Moutih Rafei
AU - Nehme El-Hachem
PY - 2026
DA - 2026/11/06
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1997527
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1997527
AB - Algorithms that predict which peptides the immune system sees are central to cancer vaccine design, yet they are trained almost entirely on binding affinity and remain largely blind to how the antigen-processing machinery shapes the repertoire that reaches the cell surface. Mesenchymal stromal cells engineered to express the immunoproteasome (MSC-IPr) are a whole-cell vaccine platform that presents a larger and chemically distinct peptide repertoire than dendritic cells. Here we use a pilot immunopeptidomics dataset from that platform to ask how much of a processing-reprogrammed repertoire current prediction models can see. Of 234 peptides detected only after tumour-lysate pulsing, 34 (14.5%) were empirically eluted from MHC class I yet scored as non-binders by NetMHCpan-4.1, MHCflurry affinity and MHCflurry presentation simultaneously. This is twenty-fold the rate obtained by applying identical criteria to an independently generated C57BL/6 immunopeptidome atlas (0.65%). These peptides are weak binders rather than true non-binders, and an orthogonal immunogenicity model ranks them modestly above the predictable majority. They are associated with a candidate non-canonical anchor pattern: an aspartate at P2 that is positional rather than compositional (3.4-fold above a composition-preserving null) and absent from catalogued H2-Db epitope space. Because the dataset comprises single mass-spectrometry runs without a proteasome-matched control, we present these as pilot observations, not established effects. We propose the engineered-processing strategy they illustrate, in which cells with defined, non-canonical processing serve as an empirical filter for epitope discovery, and we specify the replication, spectral-validation and control arms required to test it.
SN - 1664-3224
ER -